Eric Pujade-Laurine, MD, PhD, discusses the importance of homologous recombination repair deficiency (HRD) testing to provide prognostic information and detect BRCA mutations in platinum-sensitive relapsed ovarian cancer.
Eric Pujade-Laurine, MD, PhD, a medical oncologist at Hôpital Hôtel-Dieu, discusses the importance of homologous recombination repair deficiency (HRD) testing to provide prognostic information and detect BRCA mutations in platinum-sensitive relapsed ovarian cancer.
According to Pujade-Laurine, HRD testing is especially important. Not only is the test a predictive test, but it also provides valuable information about the tumor itself. If a BRCA mutation is found, it is important to send the patient for further oncogenic testing to determine if the tumor has a germline mutation.
Testing for a BRCA mutation is not only beneficial for the patient, Pujade-Laurine explains. A patient’s entire family can benefit from having this information. BRCA mutations are inherited and can be passed down to offspring. When a patient tests positive for a BRCA mutation, the rest of the family becomes more aware of their cancer risk.
Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC
March 22nd 2024In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.
Read More